Development of biological anticancer drugs based on nanotechnology

Disruptive nanotechnology solution for the treatment of aggressive cancers with a high incidence worldwide through the intracellular release of monoclonal antibodies in tumour and metastatic cells. This spin-off of the University of Santiago de Compostela has emerged from the laboratory of Professor María José Alonso, where the patented MPN Technology™ platform has been developed. MPN Technology enables progress in the use of biological drugs in the personalised treatment of cancer to treat targets that were previously unapproachable pharmacologically.

Other projects

“BioIncubaTech – High Technology Incubator for the promotion of innovation and transfer of biotechnology in the field of health and food technologies to micro and SME’s” is an operation co-financed by the European Regional Development Fund – ERDF within the Pluri-regional Operational Programme of Spain ERDF 2014-2020 OP Project “High Technology Incubators for the promotion of innovation and transfer of technology to micro and SME’s”.


  • Share: